Investigating genetic variations linked to aggressive prostate cancer in men of African and European ancestry
Official title: Contribution of germline copy number variations to the susceptibility of aggressive prostate cancer in men of African and European ancestry
Funded at University of Southern California · NIH-11050373 · Data updated 2026-11-12
This study is looking at how certain inherited genetic changes might increase the risk of aggressive prostate cancer in men from African and European backgrounds, so that we can better understand these risks and help patients learn more about their own genetic factors related to the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project start | February 1, 2025 |
| Project end | January 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $613,220 |
| NIH project number | 1R01CA285866-01A1 |
| Project ID | NIH-11050373 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men of African or European ancestry who are at risk for or diagnosed with prostate cancer.
✕Less likely to help
Patients who do not have prostate cancer or are not of African or European ancestry may not benefit from this research.
What this research studies
This research focuses on understanding how inherited genetic variations, specifically germline copy number variations (CNVs), contribute to the risk of aggressive prostate cancer in men from African and European backgrounds. By utilizing advanced techniques such as imputation and sequencing, the study aims to identify both common and rare CNVs that may influence prostate cancer susceptibility. The research will analyze existing genetic data from large-scale studies to uncover critical insights into how these variations affect disease outcomes. Patients may benefit from a better understanding of their genetic risk factors for prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to improved risk assessment and personalized treatment strategies for prostate cancer patients.
How similar studies have gone: Previous studies have shown promise in identifying genetic variations linked to prostate cancer, but this research aims to explore a less studied area of germline CNVs, making it a novel approach.
Where this research is happening
-
University of Southern California
Los Angeles, United States Active
Researchers
- Principal investigator: Chen, Fei — University of Southern California
- Study coordinator: Chen, Fei
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.